Skip to main content
NewslettersWatchlist

Mind Medicine Mindmed Inc(MNMD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.94
Day High8.55
Open:8.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Can Canada’s psychedelic drug developers shake off the sector’s bad trip?

Cybin, MindMed are set to launch expanded human studies after recent trial setbacks for Lykos, Compass
Business Wire
MindMed to Participate in Upcoming Investor Conferences
Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
Barchart
1 Small-Cap Biotech That Analysts Expect to Triple
Barchart
Buy the Dip in This Biotech After Negative FDA News, Says Analyst
Barchart
3 Growth Stocks Under $10 With Breakout Potential
Motley Fool
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
The Globe and Mail
LSD, Ecstasy, magic mushrooms coming to a clinic near you? Legalization nears for psychedelics
Barchart
Up 163% YTD, Is It Too Late to Buy MindMed Stock?
Newswire.ca
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
BayStreet.ca
This May be One of the Biggest Catalysts for Psychedelic Stocks in 2024
BayStreet.ca
Breaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSD
Barchart
3 Stocks Under $10 Analysts Expect to Double
PR Newswire
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise
PR Newswire
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
PR Newswire
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
Business Wire
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
Business Wire
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
Business Wire
MindMed to Participate in May Investor Conferences
Business Wire
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
Business Wire
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)

Profile

Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.